

# Advancing Decision-Efficiency in (Pre)-clinical Research via Novel Sequential Frameworks

Frank Konietschke

Institut für Biometrie und Klinische Epidemiologie

Charité - Universitätsmedizin Berlin, Berlin

[frank.konietschke@charite.de](mailto:frank.konietschke@charite.de)



# Sequential Tests and Monitoring

- ▶ **Pre-Clinical** Experiments
  - ▶ Animals are treated in cohorts. Results are immediately available and analyzed
  - ▶ Go/ No-Go decisions
  - ▶ Researchers stop when they feel/see efficacy

# Sequential Tests and Monitoring

- ▶ **Group-Sequential** Designs
  - ▶ Interim analysis to stop for efficacy/ futility
  - ▶ Usually one (or two) interim analysis

# Sequential Tests and Monitoring

- ▶ **Sequential** Data
  - ▶ Sequential data streams occur often
  - ▶ Wearable
  - ▶ Digital real-time biomarker

# Why Sequential Designs?

- ▶ Clinical trials are planned under uncertainty
- ▶ Assumptions on effect sizes and event rates may be wrong
- ▶ Ethical concerns:
  - ▶ exposing too many patients to inferior treatments
  - ▶ continuing trials unlikely to succeed
- ▶ Adaptive designs allow learning from accumulating data


**Goal:** More efficient, informative, and ethical trials

# Digital Biomarker


- ▷ **Real-Time Digital Biomarkers**
- ▷ Monitoring of risk in ICU patients
- ▷ Detection of arrhythmias
- ▷ Response at time point  $t$

$P(\text{Patient will event in the next six hours})$

- ▷ Response measured every 5 minutes



# Digital Real-Time Biomarker



[www-x-cardiac.com](http://www-x-cardiac.com)

# Digital Real-Time Biomarker

## Time-Dependent Sensitivity ( $Se(t)$ )


- ▶ Prob. that  $X \geq c$  at time  $t$ .
- ▶  $P(Y(t) > c(t) | D(u) = 1; 0 \leq u \leq t \leq u + \Delta)$

## Time-Dependent AUC ( $AUC(t)$ )

- ▶ AUC at a specific time horizon  $t$ .
- ▶ Summarizes discriminative power of separation

## Monitoring Framework

- ▶ Alerts
- ▶ Clinical Decision support
- ▶ Change point estimation



# Monitoring Framework





Abb.: Monitoring framework to be established for digital real-time biomarkers.

# Example: Reaction Times

## Pre-Clinical trial

Measuring reaction times [ms] in two groups (n = 10)



Group	N	Mean	SD	Med.	(Min,Max)
A	10	343.5	272.5	171.0	(210, 750)
B	10	255.0	255.0	43.1	(190, 320)


### ► Impact of the outliers:

- Mean (1:7): 253.57
- Mean (1:8): 269.38
- Mean (1:9): 298.33
- Mean (1:10): 343.50

# Descriptive Overview

## Mann-Whitney Effect Visualization

$U = 65 \mid P(A < B) = 0.35$



## ▷ Effects:

- ▷  $MW = 35\%$
- ▷  $Odds = 65\% / 35\% = 1.9$
- ▷ The chance of observing a larger reaction time in A, is 1.9 times as large

# Statistical Model

- ▷  $X_{ik} \sim F_i, \quad i = 1, 2; k = 1, \dots, n_i$
- ▷ Effect of the populations
  - ▷ Relative effect  $\theta = P(X_{11} < X_{21}) + 0.5P(X_{11} = X_{21})$
  - ▷ Interpretation
    - ▷  $\theta$  is the true proportion of the values in population 1 being smaller than those in population 2
    - ▷ If  $\theta < \frac{1}{2}$ : X1 tends to be larger than X2
    - ▷ If  $\theta = 1/2$ : No tendency to smaller or larger values

# Nonparametric Null Hypotheses

- ▶  $X_j : X_{j1}, \dots, X_{jn_j} \sim F_j, j = 1, 2; k = 1, \dots, n_j$
- ▶ Two possible ways to formulate the null hypothesis
  
- ▶  $H_0^F : F_1 = F_2$
- ▶ **Wilcoxon-Mann-Whitney Test**
- ▶ Test whether distributions are identical
- ▶ Homoscedasticity (equal variances)
- ▶ Asymptotic and Exact
  
- ▶ Remember:  $H_0^F \Rightarrow H_0^\theta$ : If  $F_1 = F_2 \Rightarrow \theta = \frac{1}{2}$
- ▶ Does the reverse also hold?
  
- ▶  $H_0 : \theta = \frac{1}{2}$
- ▶ **Nonparametric Behrens-Fisher Problem**
- ▶ Heteroscedasticity
- ▶ Unequal variances and shapes

# The Wilcoxon-Mann-Whitney Test

- ▶ Two independent samples:  $X_{ik} \sim F_i$ ,  $i = 1, 2$ ;  $k = 1, \dots, n_i$ ;  $N = n_1 + n_2$
- ▶ Under  $H_0^F : F_1 = F_2 = F$ ,

$$W_N = \frac{\hat{\theta} - \frac{1}{2}}{\hat{\sigma}_0 \sqrt{\left(\frac{1}{n_1} + \frac{1}{n_2}\right)}} \overset{\sim}{\sim} N(0, 1)$$

where

$$\hat{\sigma}_0^2 = \frac{1}{N^2(N-1)} \sum_{i=1}^2 \sum_{k=1}^{n_i} \left( R_{ik} - \frac{N+1}{2} \right)^2$$

## (Asymptotic WMW Test)

- ▶ Reject  $H_0$  at level  $\alpha$ , if  $|W_N| \geq z(1 - \alpha/2)$  :  $(1 - \alpha/2)$ -quantile from  $N(0, 1)$
- ▶ Assume:  $\sigma_0^2 = \text{Var}(F(X_{11})) > 0$  and  $\min\{n_1, n_2\} \rightarrow \infty$  such that  $N/n_i \leq N_0 < \infty$

# Variance Estimator

- ▶ No unbiased estimator of its variance (in finite n) existed
- ▶ We recently derived an unbiased estimator

$$\hat{\sigma}_N^2 = \frac{1}{n_1 n_2} \left[ (n_2 - 1) \hat{\sigma}_1^2 + (n_1 - 1) \hat{\sigma}_2^2 + \hat{\theta}(1 - \hat{\theta}) - \frac{1}{4} \hat{\tau} \right]$$

- ▶  $\hat{\sigma}_i^2$  = Estimated variance of  $\hat{F}_j(X_{ik})$
- ▶  $\hat{\tau}$ : Estimated probability of ties

- ▶  $\hat{\sigma}_N^2 \geq 0$ , unbiased and strongly consistent

REGULAR ARTICLE



An unbiased rank-based estimator of the Mann–Whitney variance including the case of ties

Edgar Brunner<sup>1</sup> · Frank Konietschke<sup>2</sup>

Received: 10 December 2023 / Revised: 21 September 2024  
© The Author(s) 2024

# The $C^2$ -Test

- ▶ The Brunner-Munzel test shows a liberal behavior when samples are (very) small
- ▶ Needed: A better approximation
- ▶ The novel  $C^2$ -Test


- ▶ Relate to the maximum variance of  $\hat{\theta}$

- ▶ 
$$\text{Var}(\hat{\theta}) \approx \frac{\hat{\sigma}_N^2}{\hat{\theta}(1-\hat{\theta})} \theta(1-\theta)$$

$$C^2 = \frac{4}{\hat{q}} \left( \hat{\theta} - \frac{1}{2} \right)^2$$

- ▶ 
$$\hat{q} = \frac{\hat{\sigma}^2}{\hat{\theta}(1-\hat{\theta})}$$

- ▶ Reject  $H_0$ , if  $C^2 \geq \chi_{1,1-\alpha}^2$



## A New Approach to the Nonparametric Behrens–Fisher Problem With Compatible Confidence Intervals

Stephen Schürhuis<sup>1</sup> | Frank Konietschke<sup>2</sup> | Edgar Brunner<sup>3</sup>

<sup>1</sup>Institute of Biometry and Clinical Epidemiology, Charit-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany | <sup>2</sup>Department of Medical Statistics, Universitätsmedizin Göttingen, Göttingen, Germany

Correspondence: Stephen Schürhuis ([stephen.schuerhuis@charite.de](mailto:stephen.schuerhuis@charite.de))

Received: 31 March 2025 | Revised: 24 September 2025 | Accepted: 18 October 2025

Keywords: Birnbaum–Klose inequality | Brunner–Munzel test | Mann–Whitney effect  $\theta$  | studentized permutation test |  $C^2$ -test

# Group Sequential Designs: Canonical Joint Distribution

## Theorem (Canonical joint law of sequential test statistics)

Let  $(Z_1, \dots, Z_K)$  denote the sequence of standardized test statistics computed at interim analyses with corresponding information levels  $0 < I_1 \leq \dots \leq I_K$ .

Then the vector  $(Z_1, \dots, Z_K)^\top$  follows a multivariate normal distribution

$$(Z_1, \dots, Z_K)^\top \sim \mathcal{N}(0, \Sigma),$$

with covariance matrix  $\Sigma = (\sigma_{ij})_{i,j=1}^K$  given by

$$\sigma_{ij} = \text{Cov}(Z_i, Z_j) = \sqrt{\frac{\min\{I_i, I_j\}}{\max\{I_i, I_j\}}}.$$

Group sequential methods for the  
Mann-Whitney parameter

Statistical Methods in Medical Research  
1-17  
© The Author(s) 2022  
  
Article reuse guidelines:  
[sagepub.com/journals-permissions](https://sagepub.com/journals-permissions)  
DOI: 10.1177/09622802221107110  
[journals.sagepub.com/home/sm](https://journals.sagepub.com/home/sm)  


Claus P Nowak<sup>1,2</sup>, Tobias Mütze<sup>3</sup>, and Frank Konietzschke<sup>1</sup>

# Group Sequential Design: Example Boundaries

Stopping boundaries:

Look (N)	O'Brien-Fleming		Pocock	
	Efficacy (Z)	$p$ (nom.)	Efficacy (Z)	$p$ (nom.)
Interim 1 (25%)	4.05	<0.0001	2.29	0.0221
Interim 2 (50%)	2.86	0.0042	2.29	0.0221
Final (100%)	2.02	0.0430	2.29	0.0221

Interpretation:

- ▶ **Efficacy boundary:** if the test statistic crosses this line, stop early for success
- ▶ Otherwise, continue until the next interim or final analysis


# Group Sequential Design: Example Boundaries

## Note


The total sample size increases of about 2 - 10 % usually

# Sequential WMW Tests


Sequential WMW, K = 10




Sequential WMW, K = 100



Sequential WMW, K = 1000



Sequential WMW, K = 10000



# Sequential Rank Tests: Continuous-Time Limit

## Theorem (Canonical Process)

Let  $Z_k$  denote the standardized rank-based test statistics at look  $k$ , with sample sizes  $(n_{1k}, n_{2k})$ . Define the information fraction

$$t_k = \frac{I_k}{I_{\max}}, \quad I_k = \begin{cases} \frac{12n_{1k}n_{2k}}{n_{1k}+n_{2k}+1}, & \text{WMW,} \\ c \frac{n_{1k}n_{2k}}{n_{1k}+n_{2k}}, & \text{BF.} \end{cases}$$


Assume  $N_k = n_{1k} + n_{2k} \rightarrow \infty$  and  $\sup_k N_k / \min(n_{1k}, n_{2k}) < \infty$ .

Then, as  $N_k \rightarrow \infty$ ,

$$\{Z(t_k) : t_k \in [t_0, 1]\} \Rightarrow \left\{ \frac{W(t)}{\sqrt{t}} : t \in [t_0, 1] \right\} \quad \text{in } D[t_0, 1],$$


where  $W(t)$  is standard Brownian motion.

## Animated Supremum and Boundaries $b(t)$




**Note:** The black path represents  $Z(t)$ ; colored curves are boundaries. The shaded area indicates where the supremum over  $[t_0, 1]$  is relevant.

## Animated Supremum and Boundaries $b(t)$




**Note:** The black path represents  $Z(t)$ ; colored curves are boundaries. The shaded area indicates where the supremum over  $[t_0, 1]$  is relevant.

## Animated Supremum and Boundaries $b(t)$




**Note:** The black path represents  $Z(t)$ ; colored curves are boundaries. The shaded area indicates where the supremum over  $[t_0, 1]$  is relevant.

## Animated Supremum and Boundaries $b(t)$




**Note:** The black path represents  $Z(t)$ ; colored curves are boundaries. The shaded area indicates where the supremum over  $[t_0, 1]$  is relevant.

## Animated Supremum and Boundaries $b(t)$




**Note:** The black path represents  $Z(t)$ ; colored curves are boundaries. The shaded area indicates where the supremum over  $[t_0, 1]$  is relevant.

## Animated Supremum and Boundaries $b(t)$




**Note:** The black path represents  $Z(t)$ ; colored curves are boundaries. The shaded area indicates where the supremum over  $[t_0, 1]$  is relevant.

## Animated Supremum and Boundaries $b(t)$




**Note:** The black path represents  $Z(t)$ ; colored curves are boundaries. The shaded area indicates where the supremum over  $[t_0, 1]$  is relevant.

## Animated Supremum and Boundaries $b(t)$




**Note:** The black path represents  $Z(t)$ ; colored curves are boundaries. The shaded area indicates where the supremum over  $[t_0, 1]$  is relevant.

## Animated Supremum and Boundaries $b(t)$



**Note:** The black path represents  $Z(t)$ ; colored curves are boundaries. The shaded area indicates where the supremum over  $[t_0, 1]$  is relevant.

## Animated Supremum and Boundaries $b(t)$



**Note:** The black path represents  $Z(t)$ ; colored curves are boundaries. The shaded area indicates where the supremum over  $[t_0, 1]$  is relevant.

# Stopping Times

## ▷ Stops with error control

- ▷ Let  $z_{1-\alpha}$  denote the  $(1 - \alpha)$ -quantile of

$$\sup_{t \in [t_0, 1]} \frac{W(t)}{\sqrt{t}},$$

where  $W(t)$  is a standard Wiener process.

- ▷ Define the stopping time

$$\tau := \inf \{t \in [t_0, 1] : Z(t) \geq z_{1-\alpha}\},$$

with the convention  $\tau = \infty$  if the boundary is never crossed.

- ▷ Reject  $H_0$  if  $\tau \leq 1$ .
- ▷ Then the type-I error probability is strongly controlled at level  $\alpha$ .

# Stopping Times with Continuous O'Brien-Fleming Boundaries

- ▶ **Continuous O'Brien-Fleming boundary:**

$$b(t) = \frac{C}{\sqrt{t}}, \quad t \in [t_0, 1]$$

where  $C$  is the constant adjusted for sequential testing (e.g.,  $C \approx 1.1 z_{1-\alpha/2}$  for  $\alpha = 0.05$ ).

- ▶ Define the stopping time

$$\tau_{\text{OF}} := \inf \{ t \in [t_0, 1] : Z(t) \geq b(t) \},$$

with  $\tau_{\text{OF}} = \infty$  if the boundary is never crossed.

- ▶ Reject  $H_0$  if  $\tau_{\text{OF}} \leq 1$ .
- ▶ Then the type-I error probability is strongly controlled at level  $\alpha$ , and early stopping is more conservative at small  $t$  due to the O'Brien-Fleming shape.

## Simulation Results: Sequential Tests

Tab.: Sequential WMW test simulation results under  $H_0$  ( $\mu_2 = 0$ ,  $\alpha = 0.05$ ,  $n_{01} = n_{02} = 10$ )

incrs	critBM	critMax	BM	Maxstat	OBF	FixedWMW	$N_{\max}$	ESS (cond/uncond)
10	2.371	2.389	0.0491	0.0474	0.0417	0.0474	40	26.16 / 39.34
30	2.587	2.579	0.0463	0.0467	0.0500	0.0494	80	39.44 / 78.11
50	2.675	2.661	0.0443	0.0454	0.0507	0.0498	120	53.26 / 116.97
100	2.755	2.764	0.0506	0.0496	0.0554	0.0493	220	80.61 / 213.09

- ▶ Type I error is well controlled at the nominal level.

# Simulation Results: Continuous-Time Sequential Tests

Tab.: Sequential WMW test simulation results under varying  $\mu_2$  ( $\alpha = 0.05$ ,  $n_{01} = n_{02} = 10$ ,  $\text{incrs} = 30$ )

$\mu_2$	critBM	critMax	BM	Maxstat	OBF	FixedWMW	$N_{\max}$	ESS (cond / uncond)
0.1	2.599	2.581	0.0560	0.0601	0.0704	0.0725	80	42.26 / 77.73
0.2	2.565	2.581	0.1087	0.1036	0.1280	0.1359	80	44.80 / 76.35
0.3	2.577	2.579	0.1821	0.1808	0.2365	0.2557	80	46.27 / 73.90
0.4	2.583	2.586	0.3031	0.3023	0.3886	0.4093	80	46.57 / 69.90
0.5	2.597	2.582	0.4401	0.4462	0.5509	0.5794	80	46.35 / 64.99
0.6	2.586	2.584	0.6026	0.6026	0.7059	0.7358	80	45.12 / 58.98
0.7	2.585	2.582	0.7553	0.7558	0.8331	0.8514	80	43.20 / 52.19
0.8	2.560	2.577	0.8604	0.8565	0.9163	0.9312	80	39.91 / 45.66
0.9	2.590	2.583	0.9291	0.9302	0.9665	0.9740	80	37.54 / 40.50
1.0	2.592	2.580	0.9694	0.9702	0.9879	0.9906	80	33.91 / 35.28

A 5x5 grid of puzzle pieces, each with a light gray fill and a dark teal outline. The pieces are arranged in a standard interlocking pattern. In the center of the grid, the words "Thank You!" are written in a bold, blue, sans-serif font.

**Thank You!**

## References

- ▶ Jennison C., Turnbull B. (2000). *Group Sequential Methods with Applications to Clinical Trials*. CRC Press.
- ▶ Pocock S. (1977). Group sequential methods in the design and analysis of clinical trials. *Biometrika*, 64, 191–199.
- ▶ OBrien P.C., Fleming T.R. (1979). A multiple testing procedure for clinical trials. *Biometrics*, 35, 549–556.
- ▶ Wald A. (1945). Sequential tests of statistical hypotheses. *Ann. Math. Statist.*, 16, 117–186.